Fresolimumab (anti-TGF beta) Improves Systemic Sclerosis
Transforming growth factor (TGF-β) is known to have potent profibrotic activity and has been implicated in the pathogenesis of systemic sclerosis a futile condition with no effective disease modifying treatments.


